Table 4 Changes in HbA1c, BMI, serum lipids and creatinine, blood pressure and dose of antidiabetic drugs (n = 33)

HbA1c (%)

10.9 ± 1.6 (9.0 – 14.4)

7.8 ± 1.5 (5.9 – 11.3)

7.4 ± 1.4 (5.5 – 12.7)

< 0.001

BMI

23.8 ± 3.3 (18.0 – 33.8)

23.5 ± 3.4 (16.8 – 32.8)

23.5 ± 3.4 (17.1 – 32.7)

0.057

Serum LDL-cholesterol (mg/dl)*

142 ± 50 (51 – 260)

128 ± 34 (61 – 213)

0.036

Serum HDL-cholesterol (mg/dl)*

52 ± 14 (30 – 77)

59 ± 16 (34 – 94)

0.008

Serum triglyceride (mg/dl)*

182 ± 189 (50 – 823)

157 ± 178 (34 – 721)

0.39

Serum creatinine (mg/dl)

0.68 ± 0.20 (0.38 – 1.20)

0.71 ± 0.21 (0.44 – 1.25)

0.21

Systolic BP (mmHg)

138 ± 17 (104 – 175)

135 ± 14 (97 – 157)

0.24

Diastolic BP (mmHg)

81 ± 11 (59 – 102)

81 ± 11 (48 – 113)

0.64

Patients with antidiabetic drugs (n)

   Glibenclamide

n = 6 (4.0 mg)

n = 3 (1.7 mg)

n = 1 (2.5 mg)

   Glimepiride

n = 1 (3.0 mg)

n = 2 (0.75 mg)

n = 0 (0 mg)

   Tolbutamide

n = 0 (0 mg)

n = 0 (0 mg)

n = 1 (500 mg)

   Metformin

n = 0 (0 mg)

n = 2 (500 mg)

n = 5 (600 mg)

   Nateglinide

n = 2 (135 mg)

n = 2 (180 mg)

n = 0 (0 mg)

   Pioglitazone

n = 0 (0 mg)

n = 0 (0 mg)

n = 2 (30 mg)

   Miglitol

n = 1 (150 mg)

n = 3 (100 mg)

n = 7 (125 mg)